$313 Million is the total value of Omega Fund Management, LLC's 21 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| REPL | Replimune Group | $81,691,000 | +2.9% | 4,673,380 | 0.0% | 26.08% | +60.6% | |
| Imago Biosciences | $40,421,000 | -30.5% | 3,018,737 | 0.0% | 12.90% | +8.4% | ||
| Cincor Pharma | $18,203,000 | +7.4% | 966,176 | 0.0% | 5.81% | +67.5% | ||
| ALPN | Alpine Immune Sciences | $17,272,000 | -5.1% | 2,029,580 | 0.0% | 5.51% | +48.0% | |
| KRON | Kronos Bio | $13,899,000 | -49.7% | 3,818,283 | 0.0% | 4.44% | -21.5% | |
| ARQT | Arcutis Biothereapeutics | $13,294,000 | +10.6% | 623,836 | 0.0% | 4.24% | +72.5% | |
| IKNA | Ikena Oncology | $9,964,000 | -27.4% | 2,249,123 | 0.0% | 3.18% | +13.2% | |
| IMUX | Immunic Inc | $6,205,000 | -69.3% | 1,788,160 | 0.0% | 1.98% | -52.1% | |
| SANA | Sana Biotechnology, Inc. | $5,425,000 | -22.2% | 843,750 | 0.0% | 1.73% | +21.5% | |
| OMEG | Omega Alpha SPAC | $4,935,000 | +0.3% | 501,000 | 0.0% | 1.58% | +56.4% | |
| Theseus Pharmaceuticals | $3,934,000 | -52.0% | 711,479 | 0.0% | 1.26% | -25.2% | ||
| PRTK | Paratek Pharmaceuticals | $3,804,000 | -35.0% | 1,971,241 | 0.0% | 1.21% | +1.3% | |
| SPRB | Spruce Biosciences | $3,760,000 | -13.4% | 2,161,022 | 0.0% | 1.20% | +35.0% | |
| SYRS | Syros Pharmaceuticals | $2,419,000 | -19.1% | 2,512,705 | 0.0% | 0.77% | +26.1% | |
| IMCR | Immunocore Holdingsads | $1,923,000 | +24.8% | 51,535 | 0.0% | 0.61% | +94.9% | |
| EPIX | ESSA Pharma | $1,034,000 | -49.0% | 328,196 | 0.0% | 0.33% | -20.5% | |
| JNCE | Jounce Therapeutics | $835,000 | -55.4% | 275,513 | 0.0% | 0.27% | -30.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | 34 | Q1 2023 | 39.1% |
| FibroGen, Inc. | 28 | Q3 2021 | 14.3% |
| Jounce Therapeutics | 25 | Q1 2023 | 11.6% |
| Pieris Pharmaceuticals | 23 | Q1 2021 | 5.2% |
| Replimune Group | 21 | Q3 2023 | 47.2% |
| Cidara Therapeutics | 20 | Q3 2021 | 5.8% |
| Morphic Holding | 18 | Q3 2023 | 22.0% |
| Immunic Inc | 18 | Q3 2023 | 9.0% |
| Dicerna Pharmaceuticals | 18 | Q1 2019 | 3.7% |
| Egalet | 17 | Q4 2018 | 19.6% |
View Omega Fund Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
View Omega Fund Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.